Clear Search sequence regions
Bookmark Forward

QuickView for Trimethobenzamide (compound)


PubChem
Name: trimethobenzamide
PubChem Compound ID: 5577
Molecular formula: C21H28N2O5
Molecular weight: 388.458 g/mol
Synonyms:
DivK1c_000425; EINECS 205-332-1; Benzamide, N-[p-[2-(dimethylamino)ethoxy]benzyl]-3,4,5-trimethoxy-, hydrochloride; Benzamide, N-((4-(2-(dimethylamino)ethoxy)phenyl)methyl)-3,4,5-trimethoxy-; 4-[(2-Dimethylamino)ethoxy]-N-(3,4, 5-trimethoxybenzoyl)benzylamine hydrochloride; Ametik hydrochloride; NCGC00016509-01; 554-92-7; KBio2_000557; Benzamide, N-[[4-[2-(dimethylamino)ethoxy]phenyl]methyl]-3,4,5-trimethoxy-.
show more »
DrugBank
Identification
Name: trimethobenzamide
Name (isomeric): DB00662
Drug Type: small molecule
Synonyms:
Trimethobenzamidum [INN-Latin]; Trimetobenzamida [INN-Spanish]; Trimethobenzamide hydrochloride; Trimethobenzamide HCL
Brand: Trimazide, Tribenzagan, Tebamide, Stemetic, Nauseton, Benzacot, Tigan, Ametik hydrochloride
Category: Antiemetics
CAS number: 138-56-7
Pharmacology
Indication: For the treatment of postoperative nausea and vomiting and for nausea associated with gastroenteritis.
Pharmacology:
Trimethobenzamide is a novel antiemetic which prevents nausea and vomiting in humans. Its actions are unclear but most likely involves the chemoreceptor trigger zone (CTZ). In dogs pretreated with trimethobenzamide HCl, the emetic response to apomorphine is inhibited, while little or no protection is afforded against emesis induced by intragastric ...
show more »
Mechanism of Action: The mechanism of action of trimethobenzamide as determined in animals is obscure, but may involve the chemoreceptor trigger zone (CTZ), an area in the medulla oblongata through which emetic impulses are conveyed to the vomiting center; direct impulses to the vomiting center apparently are not similarly inhibited.
Absorption: The relative bioavailability of the capsule formulation compared to the solution is 100%.
Biotransformation: Hepatic.
Route of elimination: Between 30 – 50% of a single dose in humans is excreted unchanged in the urine within 48–72 hours.
Half Life: The mean elimination half-life of trimethobenzamide is 7 to 9 hours.
Toxicity: Oral LD50 in mice is 1600 mg/kg.
Affected organisms: Humans and other mammals
Interactions
Drug interaction:
MethanthelineTrimethobenzamide and Methantheline, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
TrihexyphenidylTrimethobenzamide and Trihexyphenidyl, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
HyoscyamineTrimethobenzamide and Hyoscyamine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
TrimeprazineTrimethobenzamide and Trimeprazine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
DoxylamineTrimethobenzamide and Doxylamine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
show more »